This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n10http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q79162285
rdf:type
wikibase:Item
schema:description
artículu científicu espublizáu en setiembre de 2006 wetenschappelijk artikel наукова стаття, опублікована у вересні 2006 scientific article published on 12 September 2006 article scientifique publié en 2006 im September 2006 veröffentlichter wissenschaftlicher Artikel 2006 թվականի սեպտեմբերի 12-ին հրատարակված գիտական հոդված
p:P577
wds:Q79162285-2201EA55-D7D5-4778-898A-C79BBEADFA38
wdt:P577
2006-09-12T00:00:00Z
p:P407
wds:Q79162285-D80DC1DF-EECB-40FD-AE70-CAEB6D232B48
wdt:P407
wd:Q1860
p:P2093
wds:Q79162285-F969EA59-2BB4-4D4F-82CA-9A1F75587181 wds:Q79162285-27A5C42E-BB9F-48CE-BFBE-937D65DDFF66 wds:Q79162285-8BAB5089-B91F-496D-BCE5-E8526D93A1DE wds:Q79162285-6FEFDDC8-7C86-433A-94F5-BEA8FA77BAC8 wds:Q79162285-66F4B71F-9C23-4E89-A9D7-7864F37F49A2 wds:Q79162285-FC227D38-0F18-4369-9AB2-E0961B34C777
wdt:P2093
Jacques J Col Karen Pieper Charles V Pollack Marc Cohen James Hoekstra James J Ferguson
rdfs:label
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes
skos:prefLabel
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes
schema:name
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes
p:P50
wds:Q79162285-A8087119-82FF-41BE-BD7E-AE112DE2ACDA wds:Q79162285-825A8AB2-63D7-4B08-86BE-2B7FF38917A6 wds:Q79162285-84089383-4AF2-4DD6-AFB2-300515717ADB wds:Q79162285-6A87297E-DBE0-4772-A517-AA03E0DBC55B wds:Q79162285-30AD263D-3BBA-4A4D-B1D6-4F59EFA67008 wds:Q79162285-0786C0D9-E10E-423E-B39B-FE30882E1461 wds:Q79162285-17244607-BA14-4ED9-8540-4DF9C94F9A4E
wdt:P50
wd:Q1587897 wd:Q19281782 wd:Q63101609 wd:Q103008262 wd:Q64496972 wd:Q114427092 wd:Q91304252
p:P1476
wds:Q79162285-806DBBEE-04EF-40C5-8B89-1E3CB80A4773
wdt:P1476
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes
p:P304
wds:Q79162285-E43217C9-ADFD-45C5-BD32-009882616F43
wdt:P304
1346-1354
p:P31
wds:Q79162285-E1E5A864-41A3-4A02-BCB5-6DB661716EAF
wdt:P31
wd:Q13442814
p:P921
wds:Q79162285-D7A8360E-F1E4-4D49-9CF5-AC5B6506A5B0 wds:Q79162285-46C675A6-3553-49B3-90A4-4CB34890FEF3
wdt:P921
wd:Q266018 wd:Q190016
p:P698
wds:Q79162285-F62ECA9D-3C7A-4883-92ED-A86852F4958C
wdtn:P698
n9:17010793
wdt:P698
17010793
p:P1433
wds:Q79162285-1F02B65B-3239-4663-83CA-BE7615B76927
wdt:P1433
wd:Q2984355
p:P433
wds:Q79162285-9A121157-F697-48B0-BDE0-C31F5A0E8A85
p:P478
wds:Q79162285-5458EFAC-CF1E-40A7-9DFF-0D571358CBA1
wdt:P433
7
wdt:P478
48
p:P356
wds:Q79162285-CD1F8F65-84BF-4035-B030-9BB41C23DA79
wdtn:P356
n10:J.JACC.2006.05.058
wdt:P356
10.1016/J.JACC.2006.05.058
p:P8608
wds:Q79162285-DF109283-B8FB-466B-9BBD-EE0E1850B113
wdt:P8608
release_5sgkwrdgengsnnkqydn7rtr7cy